AmacaThera and Pacira BioSciences have entered a strategic collaboration to develop AMT-143, a long-acting local anesthetic aimed at enhancing pain management in clinical settings.

Target Information

AmacaThera is a company specializing in the development and commercialization of long-acting local anesthetics, specifically those based on the next-generation drug delivery technologies. Through this innovative approach, AmacaThera aims to enhance patient care by providing better pain management solutions in clinical settings. The company's lead product, AMT-143, is designed to improve the duration of analgesia in surgical applications by optimizing drug release profiles and patient comfort.

As part of a recent development initiative, AmacaThera has signed a strategic collaboration agreement with Pacira BioSciences, Inc., a leader in the field of injectable non-opioid pain management solutions. This partnership enables both companies to jointly advance the development of AMT-143, with AmacaThera leading clinical trials while Pacira supports the manufacturing and commercialization efforts.

Industry Overview

The local anesthetics market has been evolving, particularly in the United States, where there is an increasing demand for novel pain management therapies. The opioid crisis has catalyzed a shift towards non-opioid